LONDON--(BUSINESS WIRE)--Technavio has announced its market research report on gene therapy for age-related macular degeneration. This report presents a detailed analysis of the market, including indication analysis, therapeutic assessment and key companies that are expected to play an essential role in the growth of the market during the forecast period.
Gene therapy for age-related macular degeneration - market overview
Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD.
AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
The gene therapy is emerging as one of the most exciting and potentially innovative approaches for the long-lasting treatment of AMD. The gene therapy uses a virus called AAV2 that delivers a gene, which causes the retinal cells to produce a therapeutic protein and can stop the creation of abnormal blood vessels.
According to a senior analyst at Technavio for infectious and rare diseases, “The gene therapy candidates for AMD are being developed based on its two different forms namely wAMD and dAMD. About 46% of the pipeline molecules are being evaluated for wAMD, and 36% of the pipeline molecules are being evaluated for dAMD.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Gene therapy for age-related macular degeneration – segmentation analysis
The report includes an analysis of the market based on disease type (wAMD, dAMD, and unspecified AMD), assessment by RoA (subretinal, intravitreal, and unspecified), and assessment by target (VEGF, PDGFR-beta and VEGFR2, ChR2 gene, and undisclosed).
About 18% of the current pipeline molecules under investigation for AMD gene therapy are being administered through the intravitreal route. Around 18% of these molecules are being administered through the subretinal route. The remaining 64% of the pipeline therapeutics for AMD gene therapy have been placed in the unspecified category as the RoA for many of the pre-clinical and discovery molecules is not disclosed.
Technavio’s best deals of the month!
Celebrate Earth Day and clean energy with Technavio. Get 30% discount on all Energy reports. Offer valid from 12th March - 18th March.
Get 20% off on all Media and Entertainment Services reports. Offer valid only till the 31st of March.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.